SAFE Pharmaceutical Nets Nearly 200 Million RMB in Series B

SAFE Pharmaceutical recently announced that it has completed a Round B financing of nearly 200 million RMB, which is led by China Life Grand Health Fund, followed by Legend Capital and IDG Capital. Meanwhile, Probe Capital serves as the exclusive financial adviser for this round of financing. The proceeds will be used to expand the company's one-stop medical CRO platform and build an entrepreneurial platform for innovative pharmaceutical industry leaders.

SAFE Pharmaceutical was established in 2016, based on national level drug research and development units such as the Institute of Drug Innovation of the Chinese Academy of Sciences and the former National Beijing Drug Safety Evaluation and Research Center, etc. SAFE pharmaceutical is committed to become a world-class one-stop medical CRO service company and has following units/divisions: pharmaceutical development consultation, formulation and pre-formulation development, efficacy, disease animal models, pharmacokinetics, toxicology and safety evaluation, Bioanalysis, bio-equivalency, clinical phaseⅠ-III and pharmacovigilance, etc.

The company has been successively awarded the honorary titles such as national high-tech enterprises, Beijing Science and Technology Small and Medium-sized Enterprises, Zhongguancun High-Tech Enterprises, etc. SAFE owns Gu’An GLP Drug Evaluation Center, Beijing Pharmacology and Pharmacodynamics center, Shenzhen Pharmacology Evaluation Center, Sichuan Disease Animal Model Center, Beijing Physical and Chemical Characterization Center and Beijing Clinical Trial Center, Benxi Small Molecule Bioanalytical Center, Shandong Bio-Analytical Laboratory and GCP Clinical Trial Bases in four provincial grade-IIIA hospitals.

SAFE has a high-quality core research and development team whose members had been engaged in new drug research and development and evaluation for many years, with core experts from the Chinese Academy of Sciences, the Former Academy of Military Medical Sciences and various professional evaluation branch offices of the National Medical Products Administration. They have served more than 400 companies, both domestic and international, and successfully completed more than 600 non-clinical and clinical package evaluations, conducted 2,000+ non-clinical and clinical trial projects, and presided over and participated in many major new drug development projects, national 863, 973 and Natural Fund key projects. The service covers pharmacology, toxicology, pathology, pathophysiology, medical clinical examination, laboratory animal science, statistics and other specialties.

The core business of Legend Capital is early-stage Venture Capital and expansion-stage Growth Capital investment.Legend Capital is now managing several USD funds and RMB funds with a total AUM RMB50 bn, and focuses on innovation and growth enterprises with operations in China or related to China.By 2020, Legend Capital has invested in about 500+ companies, 80 are successfully listed on domestic or overseas capital market, besides, 60+ companies achieved exit through M&A.